Tag Archives: Approves

FDA Approves Retevmo (selpercatinib) for Patients with Advanced RET-Driven Lung and Thyroid Cancers

FDA Approves Retevmo (selpercatinib) for Patients with Advanced RET-Driven Lung and Thyroid Cancers Print this page INDIANAPOLIS, May 8, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules), the first therapy specifically indicated for the treatment of adult patients with… Read More »

FDA Approves Bijuva (estradiol and progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause

FDA Approves Bijuva (estradiol and progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause Print this page BOCA RATON, Fla.–(BUSINESS WIRE)–Oct. 29, 2018– TherapeuticsMD, Inc, an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved Bijuva (estradiol and progesterone) capsules, 1 mg/100… Read More »

US approves new type of flu drug

U.S. health regulators have approved the first new type of flu drug in two decades. Wednesday’s approval of Xofluza for people age 12 and older comes ahead of the brunt of this winter’s flu season. Xofluza is a pill that can reduce severity and shorten duration of flu symptoms after one just dose. It was… Read More »

FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza

FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza Print this page October 24, 2018 — Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48… Read More »

FDA Approves Third of New Migraine Drugs

Sept. 28, 2018 — The FDA has approved the third of a new type of drug to prevent migraine headaches in adults. Galcanezumab-gnlm (Emgality) targets calcitonin gene-related peptide (CGRP), a molecule that’s produced in nerve cells of the brain and spinal cord. The FDA approved two other CGRP drugs for migraine — erenumab (Aimovig) and fremanezumab-vfrm… Read More »